Navigation Links
Prolong's Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran
Date:12/15/2011

SOUTH PLAINFIELD, N.J., Dec. 15, 2011 /PRNewswire/ -- Prolong Pharmaceuticals today announced that Tom Flachmeyer has joined Prolong to spearhead the firms' engineering and facilities planning function for it oxygen therapeutic product SANGUINATE™.   Having previously directed the construction of the world's largest biotech facility to date, Wyeth's Grange Castle facility in Dublin, Ireland, Flachmeyer is charged with expanding Prolong's current cGMP production facility to support worldwide clinical development in sickle cell patients.

Tom brings an extensive background in managing technical organizations, strategic / capital planning and capital project execution and has a proven track record of executing technically complex projects. Formerly a Director of Project Management at Parsons, Life Sciences Group, Tom has held senior management positions in Engineering at Wyeth, Warner-Lambert (now Pfizer) and Foster Wheeler.  At Schering Plough he spent 5 years in Ireland and 3 years in Singapore executing large scale capital projects that delivered critical capabilities to the supply chain.

"Tom's international experience in designing high quality, large scale bio-manufacturing facilities to FDA approved status, is unparalleled in the industry," said Glenn Kazo, Prolong's President. "As lead project manager for several multinational engineering firms, and with direct experience as a bio-pharma company executive, Tom is ideally suited to drive our expansion." 

About Prolong Pharmaceuticals
Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company Prolong is focused on sickle cell anemia, diabetic ischemia, and several trauma indications. The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. For more information visit: www.prolongpharmaceuticals.com.

 


'/>"/>
SOURCE Prolong Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
2. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
5. Neptune Krill Oil, NKO(R), enters WALGREENS, the largest U.S. retail pharmacy chain, under the brand name Schiff(R) MegaRed(TM)
6. New carbon material shows promise of storing large quantities of renewable electrical energy
7. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
8. SAFC Pharma Completes Large-Scale API Manufacturing Expansion in Ireland
9. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
10. Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company
11. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 29, 2017 , ... (March 29, 2017) — Nerium ... as an active member of the Mexican Direct Selling Association A.C. (AMVD ... in relationship marketing. This professional organization fosters loyal and fair competition among companies ...
(Date:3/29/2017)... , March 29, 2017  Applied ... applying mechanistic modeling to drug research and ... collaboration with Zymeworks Inc. for quantitative systems ... therapeutics intended for the treatment of cancer. ... Zymeworks previously for GLP toxicology studies and ...
(Date:3/29/2017)... Norwood, MA (PRWEB) , ... March 29, 2017 , ... ... year centered on patient-involved research, Colpitts Clinical Trial Travel has announced that it will ... of Direct Travel, was among the first in the United States and Europe to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... is exhibiting in booth 513 at the Association of Community Cancer Centers (ACCC) ... March 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations to ...
Breaking Biology Technology:
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
Breaking Biology News(10 mins):